Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > PT, you will have to accept the fact that your money is gone

<< Previous

Bullboard Posts

Next >>

Comment by losingmyshirton Mar 31, 2022 12:27pm

73 Views

Post# 34563417

RE:RE:PT, you will have to accept the fact that your money is gone

Obviously you are not quite understanding how this works.

You seem to think that once they announce the start of Phase1, your troubles will be over and you will recoup your losses..WRONG>>>!

There is NO scientific or medical interest in R107 for a reason. Do you not yet understand what has happened here..Obviously not because in your mind just starting Phase 1 trials equates to success.

Sorry PT. you along with many others have been duped.

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting